2,030 Eli Lilly and Company $LLY Shares Sold by BDF Gestion

Key Points

• BDF Gestion cut its Eli Lilly stake by 11.3% in the third quarter, selling 2,030 shares and retaining 16,004 shares valued at approximately $18.5 million. Institutional investors still own 82.53% of the company.
• Eli Lilly reported strong operating momentum, with quarterly revenue rising 47.7% year over year to $22.97 billion and EPS of $8.38, well above the $6.40 consensus estimate. Analysts maintain a broadly positive view, with a consensus “Moderate Buy” rating and a $1,313.43 target price.
• The company’s growth outlook is supported by positive pediatric Omvoh trial results, potential European approval of the oral weight-loss drug Foundayo and a drug-delivery collaboration worth up to $1.1 billion. However, investors continue to monitor GLP-1 competition, high valuation and insulin-pricing litigation.

BDF Gestion lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 11.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,004 shares of the company's stock after selling 2,030 shares during the quarter. Eli Lilly and Company comprises 2.5% of BDF Gestion's portfolio, making the stock its 7th largest position. BDF Gestion's holdings in Eli Lilly and Company were worth $18,518,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Foguth Wealth Management LLC. lifted its holdings in Eli Lilly and Company by 729.3% in the 3rd quarter. Foguth Wealth Management LLC. now owns 5,440 shares of the company's stock worth $6,839,000 after buying an additional 4,784 shares in the last quarter. Prospera Capital Management LLC purchased a new position in Eli Lilly and Company in the 3rd quarter valued at about $500,000. First Bank & Trust grew its stake in shares of Eli Lilly and Company by 16.7% during the third quarter. First Bank & Trust now owns 1,415 shares of the company's stock valued at $1,637,000 after acquiring an additional 202 shares in the last quarter. Cottage Street Advisors LLC grew its stake in shares of Eli Lilly and Company by 2.7% during the third quarter. Cottage Street Advisors LLC now owns 2,707 shares of the company's stock valued at $3,132,000 after acquiring an additional 72 shares in the last quarter. Finally, Clark Wealth Partners grew its stake in shares of Eli Lilly and Company by 5.9% during the third quarter. Clark Wealth Partners now owns 374 shares of the company's stock valued at $433,000 after acquiring an additional 21 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Omvoh delivered positive pediatric trial results. In the Phase 3 SHINE-2 study, 81% of children with moderately to severely active ulcerative colitis achieved a clinical response after induction, while half of responders reached clinical remission after one year. Lilly plans to submit the data to regulators for a potential pediatric label expansion. Lilly Omvoh pediatric ulcerative colitis trial results
• Positive Sentiment: Foundayo and the broader GLP-1 franchise remain key growth drivers. European regulators recommended approval of Lilly’s oral weight-loss treatment Foundayo, while analysts expect it to continue gaining market share. Strong GLP-1 sales are also expected to support upcoming third-quarter results. European Union regulators recommend Foundayo approval
• Positive Sentiment: Lilly expanded its drug-delivery capabilities. The company signed a collaboration with Metis TechBio valued at up to $1.1 billion, potentially accelerating development of AI-enabled drug-delivery technology. Metis TechBio drug-delivery collaboration
• Neutral Sentiment: Lilly will present updates on several oncology candidates at the ESMO Congress, including treatments targeting ovarian, lung, thyroid and breast cancers. The data could broaden the company’s growth base, although the commercial impact remains dependent on clinical and regulatory outcomes. Lilly oncology pipeline ESMO update
• Negative Sentiment: Competition, valuation and legal exposure are weighing on sentiment. Investors are monitoring a potential GLP-1 price war with Novo Nordisk and Lilly’s dependence on a concentrated weight-loss portfolio. A Pennsylvania lawsuit also alleges that insulin manufacturers and pharmacy-benefit managers inflated insulin prices, adding regulatory and reputational risk. Eli Lilly insulin pricing lawsuit

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last quarter. Insiders own 0.14% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Morgan Stanley lifted their target price on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a report on Monday, September 28th. Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the company a "buy" rating in a research note on Tuesday, September 15th. Guggenheim raised their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a research note on Friday, September 18th. Finally, The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a "buy" rating in a report on Thursday, September 17th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $1,313.43.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,242.76 on Tuesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a one year low of $793.82 and a one year high of $1,292.65. The company's 50-day simple moving average is $1,180.34 and its 200-day simple moving average is $1,111.84. The stock has a market capitalization of $1.17 trillion, a price-to-earnings ratio of 39.92, a PEG ratio of 1.67 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period last year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts anticipate that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.